Arrowhead Expands Management Team with Appointment of Susan Boynton as Vice President Global Regulatory Affairs
PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that
Susan Boynton has been appointed Vice President, Global Regulatory
Affairs. In this role, Ms. Boynton will have overall leadership
responsibilities to direct the Company’s regulatory initiatives and
strategy, and to ensure appropriate regulatory compliance in the conduct
of all Arrowhead development programs and required reporting to the FDA
and international health authorities.
“Susan is an accomplished leader and we are excited to have her join the
Arrowhead management team,” said Christopher Anzalone, Ph.D.,
Arrowhead’s President and Chief Executive Officer. “Her experience
leading regulatory efforts through the development and commercialization
process will be extremely valuable to Arrowhead as we move ARC-520 and
ARC-AAT forward and, importantly, as we continue to expand our pipeline
of RNAi therapeutics.”
Susan Boynton is an accomplished regulatory affairs professional with 30
years of experience developing successful regulatory strategies, leading
global filings, and ensuring regulatory compliance in the U.S., EU, and
other major markets. Ms. Boynton comes to Arrowhead from Shire where she
served as Vice President, Head of Regulatory Affairs, North America and
Global Policy and Intelligence. In this capacity she was responsible for
leadership and direction of North America regulatory staff supporting
all Shire business units. As part of Shire Human Genetic Therapies, she
also previously led all regional regulatory functions including
operations, CMC, promotion, and labeling. Prior to her role at Shire,
Ms. Boynton held leadership positions in regulatory affairs at Amgen,
Abbott Laboratories, Sanofi, and Novartis in the U.S. and in Europe. Ms.
Boynton earned a Bachelor of Science in Pharmacology with Honors from
Sunderland University, U.K., a Graduate Diploma in Law from College of
Law of England and Wales, and a Masters of Jurisprudence, Health Law
from Beasley Institute of Health Law and Policy, School of Law, Loyola
University, Chicago.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate delivery platform to develop targeted drugs based
on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic
hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1
antitrypsin deficiency, and partner-based programs in obesity and
oncology.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadresearch.com/alerts.cfm.
NASDAQ Notice
As an inducement to entering into employment with the Company, on
September 29, 2014, Ms. Boynton was awarded “inducement” options and
restricted stock units (RSU) under Rule 5635(c)(4) of the NASDAQ
Marketplace Rules. The option entitles Ms. Boynton to purchase, outside
of the Company’s stockholder approved equity incentive plans, an
aggregate of up to 20,000 shares of the Company’s common stock at an
exercise price per share of $15.05, the last reported closing price of
the Company’s common stock on the date of grant. The option vests and
becomes exercisable over a period of four years from the date of grant.
Ms. Boynton was also awarded 40,000 RSUs that vest annually in three
equal installments.
Arrowhead Research Corporation
Vince Anzalone, CFA, 626-304-3400
ir@arrowres.com
or
Investor
Relations:
The Trout Group
Lauren Glaser, 646-378-2972
ir@arrowres.com
or
Media:
Russo
Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
martina.schwarzkopf@russopartnersllc.com
Source: Arrowhead Research Corporation
News Provided by Acquire Media